{
  "abstract": "Background This study evaluated biomarker profiles associated with therapeutic response and prognosis in resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant camrelizumab plus chemotherapy.Methods In this single-arm phase II trial, patients with resectable stage IIIA–IIIB NSCLC received three cycles of camrelizumab plus chemotherapy, followed by surgery. Primary endpoints were pathological complete response (pCR). Secondary endpoints included major pathological response (MPR), disease-free survival (DFS), and safety. Exploratory analyses assessed immune subsets in the tumor microenvironment (TME) and peripheral blood, cytokine profiles, circulating tumor DNA (ctDNA) dynamics, and spatial immune–tumor interactions.Results Thirty patients were enrolled (22 squamous, 8 adenocarcinoma); 27 underwent radical resection. The pCR and MPR rates were 33.3% and 50.0%, respectively. At a median follow-up of 27.2 months, the 2-year DFS rate was 77.4%. Grade≥3 treatment-related adverse events occurred in 13.3%. Achieving pCR was associated with higher baseline levels of CD8+ T cells and naïve-like T cells in both blood and TME. Elevated baseline CD8+ naïve-like T cells in both peripheral blood and tumor nests and their closer proximity to tumor cells correlated with improved DFS. Higher circulating baseline chemokine (C-C motif) ligand 3 (CCL3) levels were associated with both pCR and prolonged DFS. Postneoadjuvant treatment ctDNA positivity predicted shorter DFS, while longitudinal ctDNA monitoring identified relapse as early as 17.6 months before radiographic progression.Conclusions Baseline CD8+ naïve-like T-cell abundance and spatial proximity to tumor cells, circulating CCL3 levels, and ctDNA dynamics may serve as potential prognostic biomarkers in resectable NSCLC receiving neoadjuvant camrelizumab plus chemotherapy.Trial registration number NCT06241807.",
  "authors": [
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Guoxin Cai"
    },
    {
      "affiliations": [
        "Department of Pneumosurgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Pingping Song"
    },
    {
      "affiliations": [
        "Department of Pneumosurgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Zhendan Wang"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Jiarui Zhao"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Kaiyue Wang"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Min Li"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China",
        "School of Clinical Medicine, Shandong Second Medical University, Weifang, China"
      ],
      "name": "Xingpeng Wang"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Jingyu Zhu"
    },
    {
      "affiliations": [
        "Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"
      ],
      "name": "Jing Xu"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Baiyang Huang"
    },
    {
      "affiliations": [
        "Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"
      ],
      "name": "Xiao Han"
    },
    {
      "affiliations": [
        "Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"
      ],
      "name": "Haiyan Zhou"
    },
    {
      "affiliations": [
        "Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"
      ],
      "name": "Chao Xie"
    },
    {
      "affiliations": [
        "Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"
      ],
      "name": "Shuai Fu"
    },
    {
      "affiliations": [
        "Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"
      ],
      "name": "Hui Jia"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Feifei Teng"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Suzhen Wang"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Hongfu Sun"
    },
    {
      "affiliations": [
        "Department of PET/CT Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"
      ],
      "name": "Wanhu Li"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Jinming Yu"
    },
    {
      "affiliations": [
        "Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China",
        "School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China"
      ],
      "name": "Xue Meng"
    }
  ],
  "title": "Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study",
  "uid": "65ac60b3-b184-5c22-b53c-10f40fa81008"
}